imiquimod has been researched along with apremilast in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Egawa, S; Ito, M; Kamata, M; Mizukawa, I; Shimizu, T; Tada, Y; Takeshima, R; Uchida, H; Watanabe, A | 1 |
| Bansal, AK; Parmar, PK; Rohit, A; Sharma, N; Wasil Kabeer, S | 1 |
2 other study(ies) available for imiquimod and apremilast
| Article | Year |
|---|---|
Apremilast downregulates interleukin-17 production and induces splenic regulatory B cells and regulatory T cells in imiquimod-induced psoriasiform dermatitis.
Topics: Animals; B-Lymphocytes, Regulatory; Disease Models, Animal; Down-Regulation; Female; Humans; Imiquimod; Interleukin-17; Mice; Psoriasis; Spleen; T-Lymphocytes, Regulatory; Thalidomide | 2021 |
Nanocrystal-based gel of apremilast ameliorates imiquimod-induced psoriasis by suppressing inflammatory responses.
Topics: Animals; Disease Models, Animal; Gels; Imiquimod; Nanoparticles; Psoriasis; Skin; Thalidomide | 2022 |